NeoChord

Executive Summary

NeoChord is a privately held medical device company based in Minneapolis, MN, pioneering a transformative approach to mitral valve repair. Founded in 2008, the company developed the NeoChord Artificial Chordae Delivery System, a beating-heart, echo-guided procedure that allows for direct repair of mitral valve regurgitation without the need for cardiopulmonary bypass or cardiac arrest. This minimally invasive technique has been proven to restore normal mitral valve function, offering a compelling alternative for patients who are not ideal candidates for traditional open-heart surgery or transcatheter valve replacement. The system leverages real-time echocardiographic guidance to precisely implant artificial chordae, preserving the patient's native valve anatomy and potentially reducing procedural complexity and recovery time. While the company has established its presence in select markets, it remains privately funded and continues to focus on expanding clinical evidence and market adoption. As a private entity, NeoChord has not disclosed detailed financials or development timelines, but its technology addresses a large and underserved patient population with degenerative mitral regurgitation. The company's primary challenges include gaining broader regulatory approvals, demonstrating long-term outcomes through rigorous clinical studies, and navigating competitive pressures from established mitral valve repair and replacement technologies. To date, NeoChord has not reported any publicly available funding rounds or partnership announcements, suggesting a lean operation or reliance on internal resources. The company's future trajectory hinges on successful clinical data dissemination, potential strategic collaborations, and regulatory clearances in key markets such as the U.S. and Europe. While the innovation is promising, the lack of recent public disclosures limits visibility into near-term milestones.

Upcoming Catalysts (preview)

• Q4 2026FDA Pre-market Approval or 510(k) Clearance for Expanded Indication75% success
• Q1 2027Publication of Long-term Clinical Outcomes from Pivotal Study80% success
• Q2 2027Strategic Partnership or Distribution Agreement in Europe or Asia60% success